Atengen is pioneering a novel therapeutic approach to treat solid tumors by specifically targeting the tumor blood vessels, which are crucial for tumor survival and metastasis. This strategy leverages the unique characteristics of tumor blood vessels, which differ significantly from those in healthy tissues in terms of formation, structure, and gene expression. By focusing on a receptor that is predominantly expressed in the blood vessels of solid tumors, Atengen aims to develop drug candidates—both small molecules and antibodies—that can effectively disrupt the tumor's blood supply. This method not only enhances drug accessibility but also minimizes the risk of drug resistance, as tumor blood vessels are less likely to mutate compared to tumor cells.

The company's innovative approach has the potential to revolutionize solid tumor treatment by allowing for a tissue-agnostic method of action while maintaining high specificity. By targeting the tumor's vascular system rather than the tumor cells directly, Atengen's strategy seeks to overcome the limitations of existing therapies, which often struggle with issues such as drug resistance and tumor inaccessibility. This groundbreaking focus on the tumor blood supply represents a significant advancement in the quest for effective cancer treatments, aiming to improve outcomes for patients with solid tumors.

United States

Atengen is developing drugs that specifically target the tumor blood vessels of most solid tumors. The long-term goal is to develop a new generation of drugs that can be used in combination with existing cancer therapies to improve patient outcomes.

Atengen

Company Details